

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	<del>Unknown</del> 10/694,245
Filing Date	<del>Even Date Herewith</del> 10/27/2003
First Named Inventor	Morris, Timothy
Group Art Unit	<del>Unknown</del> 1641
Examiner Name	Grun, James

Sheet 1 of 7

Attorney Docket No: 1133.005US2

**US PATENT DOCUMENTS**

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
JLG	US-5,731,147	03/24/1998	Bard, A., et al.	435	6	06/07/1995
↓	US-5,807,538	09/15/1998	Dean, Richard T., et al.	424	1.69	06/07/1995
↓	US-5,876,947	03/02/1999	Kudryk, B., et al.	435	7.1	07/25/1997
↓	US-6,066,448	05/23/2000	Wohlstadter, J. N., et al.	435	6	03/06/1996
JLG	US-6,078,782	06/20/2000	Leland, J. K., et al.	455	6	06/07/1995

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
JLG	WO-99/05176	02/04/1999	Kudryk, Bohdan J., et al.	C07K	16/36	

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JLG		"Urokinase Pulmonary Embolism Trial, Phase 1 Results", <u>JAMA</u> , 214(12), (1970), pp. 2163-2172	
↓		BECKER, D. M., et al., "D-Dimer Testing and Acute Venous Thromboembolism", <u>Arch. Intern. Med.</u> , 156, (1996), pp. 939-946	
↓		BELL JR, W., "Defibrinogenating Enzymes", <u>Drugs</u> , (1997), pp. 18-31	
↓		BILEZIKIAN, S. B., et al., "Radioimmunoassay of Human Fibrinopeptide Beta and Kinetics of Fibrinopeptide Cleavage by Different Enzymes", <u>The Journal of Clinical Investigation</u> , 56, (1975), pp. 438-445	
↓		BILEZIKIAN, S. B., et al., "Radioimmunoassay of human fibrinopeptide beta and kinetics of fibrinopeptide cleavage by different enzymes", <u>J. of Clinical Investigation</u> , Vol. 56, No. 2, XP002914824, (Aug 1975), 438-445	
↓		BINI, A., et al., "Degradation of Cross-Linked Fibrin by Matrix Metalloproteinase 3 (Stromelysin 1): Hydrolysis of the gamma GGly-Ala 405 Peptide Bond", <u>Biochemistry</u> , 35, (1996), pp. 13056-13063	
↓		BINI, A., et al., "Fibrin and its Derivatives in the Normal and Diseased Vessel Wall", <u>Annals New York Academy of Sciences</u> , 667, (1992), pp. 112-126	
↓		BINI, A., et al., "Flow and Antibody Binding Properties of Hydrated Fibrins Prepared from Plasma, Platelet Rich Plasma and Whole Blood", <u>Thrombosis Research</u> , 76(2), (1994), pp. 145-156	
↓		BINI, A., et al., "Identification and Distribution of Fibrinogen, Fibrin, and Fibrin(ogen) Degradation Products in Atherosclerosis", <u>Arteriosclerosis</u> , 9(1), (1989), pp. 109-121	
↓		BINI, A., et al., "Immunohistochemical Characterization of Fibrinogen, Fibrin I, and Fibrin II in Human Thrombi and Atherosclerotic Lesions", <u>Blood</u> , 69(4), (1987), pp. 1038-1045	
JLG		BINI, A., et al., "Immunohistochemical Characterization of Fibrin (ogen)-Related	

EXAMINER

/James L. Grun/

DATE CONSIDERED

02/15/2007

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)	Complete if Known	
	Application Number	Unknown 10/694,245
	Filing Date	Even Date Herewith
	First Named Inventor	Morris, Timothy
	Group Art Unit	Unknown
	Examiner Name	Grun, James
Sheet 2 of 7	Attorney Docket No: 1133.005US2	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
↑		Antigens in Human Tissues Using Monoclonal Antibodies", <u>Laboratory Investigation</u> , 60(6), (1989),pp. 814-821	
JLG		BOUNAMEAUX, H. , et al., "Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism", <u>The Lancet</u> , 337, (1991),pp. 196-200	
		BOUNAMEAUX, H. , et al., "Value of Liquid Crystal Contact Thermography and Plasma Level of D-Dimer for Screening of Deep Venous Thrombosis Following General Abdominal Surgery", <u>Thrombosis and Haemostasis</u> , 67, (1992),pp. 603-606	
		BOVILL, E. , et al., "Performance Characteristics of Fibrinogen Assays", <u>Arch. Pathol. Lab. Med.</u> , 117, (1993),pp. 58-66	
		BRANDT, J. T., et al., "Laboratory Monitoring of Heparin. Effect of Reagents and Instruments on the activated Partial Thromboplastin Time", <u>Amer. J. Clin. Pathol.</u> , 76, (1981),pp. 530-537	
		BURROWS, C. M., et al., "A New Plasma Assay To Detect Thrombosis Associated with Acute PE and DVT", <u>American Journal of Respiratory and Critical Care Medicine</u> , (1999),page 1	
		CAMPBELL, A. , <u>Monoclonal Antibody and Immunosensor Technology</u> , 23, Elsevier Sciences Publishers, Amsterdam,(1991),pp. 3-6, 20-23, 42-4	
		CARRIE, D. , et al., "A comparison of the antithrombotic effects of heparin and of low molecular weight heparins with increasing antifactor Xa/antifactor IIa ratio in the rabbit", <u>British Journal of Haematology</u> , 83, (1993),pp. 622-626	
		CARRIE, D. , et al., "Effects of Heparin, Dermatan Sulfate and of their Association on the Inhibition of Venous Thrombosis Growth in the Rabbit", <u>Thrombosis and Haemostasis</u> , (1992),pp. 637-641	
		CHUNG, D. W., et al., "Characterization of Complementary Deoxyribonucleic Acid and Genomic Deoxyribonucleic Acid for the Beta Chain of Human Fibrinogen", <u>Biochemistry</u> , 22, (1983),pp. 3244-3250	
		COLLEN, D. , et al., "Basic and Clinical Aspects of Fibrinolysis and Thrombolysis", <u>Blood</u> , 78(12), (1991),pp. 3114-3124	
		DALEN, J. E., "American College of Chest Physicians and the National Heart, Lung and Blood Institute National Conference on Antithrombotic Therapy", <u>Arch. Intern. Med.</u> , 146, (1986),pp. 462-472	
		DOUKETIS, J. D., et al., "Risk of Fatal Pulmonary Embolism in Patients with Treated Venous Thromboembolism", <u>JAMA</u> , 279, (1998),pp. 458-462	
		DYR, J. E., et al., "Conversion of fibrinogen to fibrin induced by preferential release of fibrinopeptide beta", <u>Biochemica et Biophysica Acta</u> , 990, (1989),pp. 18-24	
↓		EBERT, R. F., et al., "Assay of Human Fibrinopeptides by High-Performance Liquid Chromatography", <u>Analytical Biochemistry</u> , 148, (1985),pp. 70-78	
JLG		ECKHARDT, T. , et al., "Measurement of Desarginine Fibrinopeptide B in Human Blood", <u>J.Clin. Invest.</u> , (March 1981),pp. 809-816	

EXAMINER

/James L. Grun/

DATE CONSIDERED

02/15/2007

Substitute Disclosure Statement Form (PTO-1449)  
\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)	Complete if Known	
	Application Number	Unknown 10/694,245
	Filing Date	Even Date Herewith
	First Named Inventor	Morris, Timothy
	Group Art Unit	Unknown
	Examiner Name	Grun, James
Sheet 3 of 7	Attorney Docket No: 1133.005US2	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JLG		FU, Y., et al., "Carboxyl-Terminal-Extended Variant of the Human Fibrinogen alpha Subunit: A Novel Exon Conferring Marked Homology to beta and gamma Subunits", <u>Biochemistry</u> , 31, (1992),pp. 11968-11972	
		FU, Y., et al., "Fib420: A normal human variant of fibrinogen with two extended alpha chains", <u>Proc. Natl. Acad. Sci. USA</u> , 91, (March 1994),pp. 2625-2628	
		GANDO, S., et al., "Diagnostic and Prognostic Value of Fibrinopeptides in Patients with Clinically Suspected Pulmonary Embolism", <u>Thrombosis Research</u> , 75(2), (1994),pp. 195-202	
		GAWOSKI, J. M., et al., "The Effects of Heparin on the Activated Partial Thromboplastin Time of the College of American Pathologists Survey Specimens", <u>Arch. Pathol. Lab Med.</u> , 111, (September 1987),pp. 785-790	
		GINSBERG, J. S., et al., "Application of Novel and Rapid Whole Blood Assay for D-Dimer in Patients with Clinically Suspected Pulmonary Embolism", <u>Thromb Haemost</u> , 73, (1995),pp. 35-38	
		GINSBERG, J. S., et al., "D-Dimer in Patients with Clinically Suspected Pulmonary Embolism", <u>Chest</u> , 104, (1993),pp. 1679-1684	
		GOLDHABER, S. Z., et al., "Quantitative Plasma D-dimer Levels Among Patients Undergoing Pulmonary Angiography for Suspected Pulmonary Embolism", <u>JAMA</u> , 270, (1993),pp. 2819-2822	
		GOLDHABER, S. Z., et al., "Risk Factors for Pulmonary Embolism, The Framingham Study", <u>The American Journal of Medicine</u> , (1983),pp. 1023-1028	
		HARLOW, E., et al., <u>Antibodies: A Laboratory Manual</u> , Cold Springs Harbor Laboratory, (1998),pp. 72-77, 600-612	
		HIGGINS, D. L., et al., "Steady State Kinetic Parameters for the Thrombin-catalyzed Conversion of Human Fibrinogen to Fibrin", <u>The Journal of Biological Chemistry</u> , 258, (1983),pp. 9276-9282	
		HIRSCH, D. R., et al., "Prevalence of Deep Venous Thrombosis Among Patients in Medical Intensive Care", <u>JAMA</u> , (1995),pp. 335-337	
		HIRSCH, D. R., et al., "Shortened hospitalization by means of adjusted-dose subcutaneous heparin for deep venous thrombosis", <u>Am. Heart J.</u> , 131, (1996),pp. 276-280	
		HOELLERICH, V. L., et al., "Diagnosing Pulmonary Embolism Using Clinical Findings", <u>Arch. Intern. Med.</u> , 146, (1986),pp. 1699-1704	
		HUI, K. Y., et al., "Monoclonal antibodies to a synthetic fibrin-like peptide bind to human fibrin but not fibrinogen", <u>Science</u> , Vol. 222, XP002080953, (Sep. 1, 1983),1130	
		HULL, R., et al., "Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein Thrombosis", <u>The New England Journal of Medicine</u> , 315, (1986),pp. 1109-1114	
JLG		HULL, R. D., et al., "Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein	

EXAMINER /James L. Grun/

DATE CONSIDERED 02/15/2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)	Complete if Known	
	Application Number	<del>Unknown</del> 10/694,245
	Filing Date	<del>Even Date Herewith</del>
	First Named Inventor	Morris, Timothy
	Group Art Unit	<del>Unknown</del>
	Examiner Name	Grun, James
Sheet 4 of 7	Attorney Docket No: 1133.005US2	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
↑  JLG  ↓  JLG		Thrombosis", <u>Low-Molecular-Weight Heparin for Proximal-Vein Thrombosis</u> , 326(15), (1992),pp. 975-982	
		HULL, R. D., et al., "The Importance of Initial Heparin Treatment on Long-term Clinical Outcomes of Antithrombotic Therapy", <u>Arch. Intern. Med.</u> , 157, (1997),pp. 2317-2321	
		KAIZU, K., et al., "Role of Intrarenal Coagulation and Anticoagulant Therapy in the Progression of Diabetic Nephropathy", <u>Japanese J. of Nephrology</u> , Vol. 35, No. 1, XP002154952, (Jan. 1993),35-42	
		KINJOH, K., et al., "Production of a Monoclonal Antibody Against Rabbit Fibrinopeptide B(FPB) for Immunological Assay of Rabbit FPB", <u>Japanese Journal of Physiology</u> , 44, Abstract 272,(1994),pg. S 117	
		KOOPMAN, J., et al., "Fibrinogen Marburg: A Homozygous Case of Dysfibrinogenemia, Lacking Amino Acids A alpha 461-610 (Lys 461 AAA Stop TAA)", <u>Blood</u> , 80, (1992),pp. 1972-1979	
		KOOPMAN, M., et al., "Treatment of Venous Thrombosis with Intravenous Unfractionated Heparin Administered in the Hospital as Compared with Subcutaneous Low-Molecular-Weight Heparin Administered at Home", <u>The New England Journal of Medicine</u> , (1996),pp. 682-687	
		KUDRYK, B., et al., "A Monoclonal Antibody with Ability to Distinguish between Nh2-Terminal Fragments Derived from Fibrinogen and Fibrin", <u>Molecular Immunology</u> , 20, (1983),pp. 1191-1200	
		KUDRYK, B., et al., "Cross-linking of fibrinogen by tissue transglutaminase: Involvement of the C-termini of the Aalpha-and gamma-chains in formation of A alpha gamma - dyads", <u>Thromb. Haemostas</u> , 69(6), (1993),pg. 1260	
		KUDRYK, B., et al., "Measurement in Human Blood of Fibrinogen/Fibrin Fragments Containing the Bbeta 15-42 Sequence", <u>Thrombosis Research</u> , 25, (1982),pp. 277-291	
		KUDRYK, B., et al., "Modulation of Epitope Expression at C-Terminus Fibrinogen Chain", <u>Thrombosis and Haemostas</u> , 65, Abstract 714,(1991),pp. 898	
		KUDRYK, B. J., et al., "Monoclonal Antibodies as Probes for Fibrin(ogen) Proteolysis", <u>Monoclonal Antibodies in Immunoscintigraphy</u> , CRC Press, Inc. Florida,(1989),pp. 365-398	
		KUDRYK, B., et al., "Specificity of a Monoclonal Antibody for the NH2-Terminal Region of Fibrin", <u>Molecular Immunology</u> , 21, (1984),pp. 89-94	
		KUDRYK, B., et al., "Use of a Synthetic Homologue of Human Fibrinopeptide A for Production of a Monoclonal Antibody Specific for the Free Peptide", <u>Blood</u> , 74, (1989),pp. 1036-1044	
		LEVINE, M., et al., "A Comparison of Low-Molecular-Weight Heparin Administered Primarily at Home with Unfractionated Heparin administered in the Hospital for Proximal Deep-Vein Thrombosis", <u>The New England Journal of Medicine</u> , 334, (1996),pp. 677-681	

EXAMINER

/James L. Grun/

DATE CONSIDERED

02/15/2007

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	<del>Unknown</del> 10/694,245
Filing Date	<del>Even Date Herewith</del>
First Named Inventor	Morris, Timothy
Group Art Unit	<del>Unknown</del>
Examiner Name	Grun, James

Sheet 5 of 7

Attorney Docket No: 1133.005US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JLG		LOIKE, J. D., et al., "CD11c/CD18 on neutrophils recognizes a domain at the N terminus of the Aalpha chain of fibrinogen", <u>Proc. Natl. Acad. Sci. USA</u> , <b>88</b> , (1991),pp. 1044-1048	
		LOPACIUK, S., et al., "Subcutaneous Low Molecular Weight Heparin versus Subcutaneous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis: a Polish Multicenter Trial", <u>Thrombosis and Haemostasis</u> , <b>68</b> (1), (1992),pp. 14-18	
		LUI, C. Y., et al., "Immunologic Identification of the Cleavage Products from the Aalpha-and Bbeta-Chains in the Early Stages of Plasmin Digestion of Fibrinogen", <u>Thrombosis and Haemostasis</u> , <b>56</b> (1), (1986),pp. 100-106	
		MARSH, J. J., et al., "Supression of Thrombolysis in a Canine Model of Pulmonary Embolism", <u>Circulation</u> , <b>90</b> , (1994),pp. 3091-3097	
		MEYER, G., et al., "Subcantaneous Low-Molecular-Weight Heparin Fragmin Versus Intravenous Unfractionated Heparin in the Treatment of Acute Non Massive Pulomony Embolism: An Open Randomized Pilot Study", <u>Thrombosis and Haemostatis</u> , (1995),pp. 1432-1435	
		MILLER, G. J., et al., "The Effects of Quality and Timing of Venepuncture on Markers of Blood Coagulation in Healthy Middle-aged Men", <u>Thrombosis and Haemostatis</u> , (1995),pp. 82-86	
		MORRIS, T., et al., "Anti-fibrin Monoclonal Antibodies Detect Deep Vein Thrombosis in a Canine Model", <u>Chest</u> , <b>104</b> , Abstract,(1993),pg. 24S	
		MORRIS, T., et al., "Anti-thrombotic Efficacies of Enoxaparin, Dalteparin, and Unfractioned Heparin in Venous Thrombi-embolism", <u>Thrombosis Research</u> , <b>100</b> , (2000),pp. 185-194	
		MORRIS, T. A., et al., "Antibodies Against the Fibrin Beta-Chain Amino-Terminus Detect Active Canine Venous Thrombi", <u>Circulation</u> , <b>96</b> (9), (1997),pp. 3173-3179	
		MORRIS, T. A., et al., "Degree of Polymer Organization Decreases the Binding of a Monoclonal Antibody Raised against the Beta-Chain Amino Terminus of Fibrin", <u>Thrombosis and Haemmostasis</u> , (1997),pp. 704-709	
		MOSER, K. M., et al., "Study of Factors that May Condition Scintigraphic Detection of Venous Thrombi and Pulmonary Emboli with Indium-111-Labeled Platelets", <u>The Journal of Nuclear Medicine</u> , <b>21</b> (11), (1980),pp. 1051-1058	
		NAIM, J. O., et al., "The generation of antibody inmice to tuftsin a naturally occurring phagocytosis stimulating tetrapeptide", <u>Immunological Investigations</u> , Vol. 20, No. 4, XP002154954, (1991),351-364	
		NG, A. S., et al., "(20) Quantifying Thrombin-Catalyzed Release of Fibrinopeptides from Fibrino Using High-Performance Liquid Chromatography", <u>Methods in Enzymology</u> , <b>222</b> , (1993),pp. 341-358	
JLG		OWENS, R. J., et al., "The genetic engineering of Monoclonal antibodies", <u>J. of Immunological Methods</u> , Vol. 168, XP002914829, (1994),149-165	

EXAMINER

/James L. Grun/

DATE CONSIDERED

02/15/2007

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) 1 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number ~~Unknown~~ 10/694,245Filing Date ~~Even Date Herewith~~

First Named Inventor Morris, Timothy

Group Art Unit ~~Unknown~~

Examiner Name Grun, James

Sheet 6 of 7

Attorney Docket No: 1133.005US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JLG		PLOW, E. F., et al., "Surface Markers of Fibrinogen and Its Physiologic Derivatives Revealed by antibody Probes", <u>Seminars in Thrombosis and Hemostasis</u> , 8(1), (1982), pp. 36-56	
		PROCYK, R., et al., "Accessibility of Epitopes on Fibrin Clots and Fibrinogen Gels", <u>Blood</u> , 77(7), (1991), pp. 1469-1475	
		QURESHI, G. D., et al., "In-Vitro Stability of Human Fibrin Peptide B", <u>Thromb. Haemostasis</u> , 42, Abstract Only, (1979), 1316-1323	
		RASCHKE, R. A., et al., "The Weight-based Heparin Dosing Nomogram Compared with a "Standard Care" Nomogram", <u>Ann. Intern. Med.</u> , (1993), pp. 874-881	
		REBER, G., et al., "A new, semi-quantitative and individual ELISA for rapid measurement of plasma d-dimer in patients suspected of pulmonary embolism", <u>Blood Coagulation and Fibrinolysis</u> , 6, (1995), pp. 460-463	
		SHIBATA, K., et al., "Intraglomerular Coagulation and Fibrinolysis in Human Primary Glomerular Diseases", <u>Japanese J. of Nephrology</u> , Vol. 33, No. 8, XP002154953, (Aug 1991), 719-729	
		SINGER, I., et al., "VDIPEN, A Metalloproteinase-generated Neopeptide, Is Induced and Immunolocalized in Articular Cartilage during Inflammatory Arthritis", <u>Journal of Clinical Investigation</u> , (1995), pp. 2178-2186	
		SOUTHAN, C., et al., "Direct analysis of plasma fibrinogen-derived fibrinopeptides by high-performance chromatography: investigation of nine congenital fibrinogen abnormalities", <u>British Journal of Haematology</u> , 65, (1987), pp. 469-473	
		SOUTHAN, E., et al., "Direct Analysis of Plasma Fibrinogen-Derived Fibrinopeptides by High-Performance Liquid Chromatography", <u>Thrombosis Research</u> , 43, (1986), pp. 195-204	
		TAPSON, V. F., et al., "American Thoracic Society Position Paper: The Diagnostic Approach to Acute Venous Thromboembolism", <u>American Journal of Respiratory and Critical Care Medicine</u> , (1999), pp. 1044-1066	
		URANO, T., et al., "Fibrinogenolysis and Fibrinolysis in Normal Volunteers and Patients with Thrombosis after Infusion of Urokinase", <u>Thrombosis Research</u> , 39, (1985), 145-155	
		VALENZUELA, R., et al., "Immunoelectrophoretic and Immunohistochemical Characterizations of Fibrinogen Derivatives in Atherosclerotic Aortic Intimas and Vascular Prosthesis Pseudo-intimas", <u>American Journal of Pathology</u> , 141, (1992), pp. 861-880	
		VAN BEEK, E., et al., "The role of plasma D-dimer concentration in the exclusion of pulmonary embolism", <u>British Journal of Haematology</u> , 92, (1996), pp. 725-732	
JLG		VAN DEN BESSELAAR, A., et al., "Monitoring Heparin Therapy: Relationships between the Activated Partial Thromboplastin Time and Heparin Assays Based	

EXAMINER

/James L. Grun/

DATE CONSIDERED

02/15/2007

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) : Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  
**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)

Complete if Known

Application Number	<del>Unknown</del> 10/694,245
Filing Date	<del>Even Date Herewith</del> 10/27/2003
First Named Inventor	Morris, Timothy
Group Art Unit	<del>Unknown</del> 1641
Examiner Name	Grun, James

Sheet 7 of 7

Attorney Docket No: 1133.005US2

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
↑		on Ex-Vivo Heparin Samples", <u>Thrombosis and Haemostasis</u> , 63, (1990),pp. 16-23	
JLG		VAN HULSTEIJN, H. , et al., "Diagnostic Value of Fibrinopeptide A and Beta-Thromboglobulin i Acute Deep Venous Thrombosis and Pulmonary Embolism", <u>Acta. Med. Scand.</u> , 211, (1982),pp. 323-330	
		VERSTRAETE, M. , "Direct Thrombin Inhibitors: Appraisal of the Antithrombotic/Hemorrhagic Balance", <u>Thrombosis and Haemostasis</u> , 78, (1997),pp. 357-363	
		WALENGA, J. , et al., "Biochemical and Pharmacologic Rationale for the Development of a Synthetic Heparin Pentasaccharide", <u>Thrombosis Research</u> , 86, (1997),pp. 1-36	
		WEISSBACH, L. , et al., "Bipartite mRNA for chicken alpha-fibrinogen potentially encodes an amino acid sequence homologous to beta- and gamma-fibrinogens", <u>Proc. Natl. Acad. Sci., USA</u> , 87, (1990),pp. 5198-5202	
↓		WILNER, G. D., et al., "Immunochemical analysis of Rabbit antihuman fibrinopeptide B antibodies", <u>Biochemistry</u> , 18, XP002914823, (1979),5078-5082	
JLG		YUNG, G. L., et al., "Fibrinopeptide A Levels in Primary Pulmonary Hypertension", <u>American Journal of Respiratory and Critical Care Medicine</u> , 157, Abstract,(1998),pp. A592	

EXAMINER

/James L. Grun/

DATE CONSIDERED

02/15/2007

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached